Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for reducing blood loss in pediatric hip osteotomies
2022-002384-30Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid in hip dysplasia (DDH) (2 arms), sponsored by Erasmus MC. Primary endpoint: Estimated intraoperative blood loss. Started Sep 2022; status: active.
02
Drugs
tranexamic acid
03
Conditions
hip dysplasia (DDH)
Beyond the preview
Go deeper on 2022-002384-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002384-30.